Efficacy of corticosteroids in treatment of hospitalized patients with novel coronavirus infection (COVID-19)


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The aim of the study was the examination of the efficacy of a short corticosteroid usage course in patients with moderate COVID-19 run relatively to the dynamics of generalized inflammation. Material and methods. A retrospective analysis of patients (n=61) admitted from October 1 to November 30, 2020 with COVID-19 was carried out. The diagnosis, assessment of severity and corticosteroids prescribing procedure was carried out in accordance with the recommendations «Prevention, diagnosis and treatment of new coronavirall infection (COVID-19), version 8». Results. Male patients prevailed among the studied patients - 52 (85,2%), concomitant pathology was represented in 32 patients (52,4%), 56 (91,8%) persons recovered, 3 (4,9%) died. 31 patients received corticosteroids: 30 - dexamethasone in a course dose of 113,3±5,9 (40-216) mg, 1 - methylprednisolone 1 g for 3 days. Treatment with these medicines was started on 7,4±0,5 (2-14) days of the disease or on 2,2±0,3 (1-9) days of hospitalization; the duration of administration was 7,4±0,4 (2-12 ) days. When comparing the groups that received and did not receive corticosteroids, significant differences in indicators of inflammation (body temperature, C-reactive protein level), respiratory disorders (respiratory rate, oxygen saturation), lymphopenia and thrombocytopenia were revealed. After the withdrawal of corticosteroids, 23 (73%) patients did not require an escalation of anti-inflammatory therapy, their number of lymphocytes (by 83%), platelets (by 74%) increased, C-reactive protein decreased twice, which indicates a significant effect of these medicines at the intensity of inflammation, macrophage activation and bone marrow response. In 8 from 30 (27%) patients, treatment with corticosteroids was insufficient, which required an escalation of therapy. Conclusion. A retrospective analysis of clinical and laboratory data from patients with moderate COVID-19 course showed a significant decrease in the activity of generalized inflammation after a short course of corticosteroids.

Texto integral

Acesso é fechado

Sobre autores

Dmitry Efremov

A.A. Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of Russia

Email: efremov-d24@mail.ru
head of the infectious disease center, branch No. 1 143409, Krasnogorsk, 11 Svetlaya Str

Vladimir Beloborodov

Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia

Email: belvb1070@mail.ru
MD, professor, head of the Department of infectious diseases 125284, Moscow, 5/7 2nd Botkinsky proezd Str

Ilya Kovalev

Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia

Email: ilynemsa@gmail.com
postgraduate student of the Department of infectious diseases 125284, Moscow, 5/7 2nd Botkinsky proezd Str

Andrey Meshkov

A.A. Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of Russia

Email: 3hospital_f1@mil.ru
head of branch No. 1 143409, Krasnogorsk, 11 Svetlaya Str

Bibliografia

  1. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62. doi: 10.1016/S0140-6736(20)30566-3.
  2. Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-13. doi: 10.1016/S0140-6736(20)30211-7.
  3. Cao J., Tu W.-J., Cheng W. et al. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71(15): 748-55. doi: 10.1093/cid/ciaa243.
  4. Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46(5): 846-48. doi: 10.1007/s00134-020-05991-x.
  5. Carsana L., Sonzogni A., Nasr A. et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020. 20(10): 1135-40. doi: 10.1016/S1473-3099(20)30434-5.
  6. de Jong M.D., Simmons C.P., Thanh T.T. et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12(10): 1203-07. doi: 10.1038/nm1477.
  7. Wong C.K., Lam C.W.K., Wu A.K.L. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004; 136(1): 95-103. doi: 10.1111/j.1365-2249.2004.02415.x.
  8. Baillie J.K., Digard P. Influenza - time to target the host? N Engl J Med. 2013; 369(2): 191-93. doi: 10.1056/ NEJMcibr1304414.
  9. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5.
  10. Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020; 368(6490): 473-74. doi: 10.1126/ science.abb8925.
  11. Shang L., Zhao J., Hu Y. et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020; 395(10225): 683-84. doi: 10.1016/S0140-6736(20)30361-5.
  12. Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet.2020; 395(10223): 473-75. doi: 10.1016/S0140-6736(20)30317-2.
  13. Dagens A., Sigfrid L., Cai E. et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ. 2020; 369: m1936. doi: 10.1136/bmj.m1936.
  14. Zhao J.P., Hu Y., Du R.H. et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(3): 183-84. doi: 10.3760/cma.j.issn.1001-0939.2020.03.008.
  15. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-69. doi: 10.1001/jama.2020.1585.
  16. Xu X.W., Wu X.X., Jiang X.G. et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020; 368: m606. doi: 10.1136/bmj.m606.
  17. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 8 (03.09.2020). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf (дата обращения - 02.04.2021).
  18. Ramamoorthy S., Cidlowski J.A. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016; 42(1): 15-31. doi: 10.1016/j.rdc.2015.08.002.
  19. Timmermans S., Souffriau J., Libert C. A general introduction to glucocorticoid biology. Front Immunol. 2019; 10: 1545. doi: 10.3389/fimmu.2019.01545.
  20. Arabi Y.M., Mandourah Y., AlHameed F. et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018; 197(6): 757-67. doi: 10.1164/rccm.201706-1 172OC.
  21. Lansbury L.E., Rodrigo C., LeonardiBee J. et al. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated cochrane systematic review and meta-analysis. Crit Care Med. 2020; 48(2): e98-e106. doi: 10.1002/14651858. CD010406.pub3.
  22. WHO. World Health Organization. Geneva: Jan 28, 2020. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. URL: https://www.who.int/publications-detail/clinical-management-of-severeacuterespiratoryinfectionwhen-novelcoronavirus(ncov)infectionissuspected (date of access - 02.04.2021).
  23. Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020; 582(7813): 469-69. doi: 10.1038/d41586-020-01824-5.
  24. Zha L., Li S., Pan L. et al. Corticosteroid treatment of patients with Coronavirus Disease 2019 (COVID19). Med J Aust. 2020; 212(9): 416-20. doi: 10.5694/mja2.50577.
  25. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. Preliminary Report. N Engl J Med. 2020; 17: NEJMoa2021436. doi: 10.1056/NEJMoa2021436.
  26. Selvaraj J., Sardar H., Vishnupriya V. et al. Molecular docking analysis of amyloid precursor protein with compounds from the Australian cowplant. Bioinformation. 2020; 16(7): 561-66. doi: 10.6026/97320630016561.
  27. Manjili R.H., Zarei M., Habibi M. et al. COVID19 as an acute inflammatory disease. J Immunol. 2020; 205(1): 12-19. doi: 10.4049/jimmunol2000413.
  28. Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15): 762-68. doi: 10.1093/cid/ciaa248.
  29. Cui W., Fan Y., Wu W. et al. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 2003; 37(6): 857-59. doi: 0.1086/378587.
  30. Chen Y., Feng Z., Diao B. et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) directly decimates human spleens and lymph nodes. medRxiv. 2020. doi: 10.1101/2020.03.27.20045427.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies